Navigation Links
Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Date:11/12/2009

NEW BRUNSWICK, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) announced today that Catherine Taylor, one of the Company's funded researchers, will be presenting pre-clinical stability and biological activity data on SNS-01, Senesco's multiple myeloma drug candidate, at the 2009 American Association for Cancer Research (AACR)-National Cancer Institute (NCI)-European Organization for Research and Treatment of Cancer (EORTC) Molecular Targets and Cancer Therapeutics Conference. Ms. Taylor is a member of the Department of Biology at the University of Waterloo, Ontario, Canada. The conference will take place from Sunday, November 15th through Thursday, November 19th, in Boston, MA. Ms. Taylor's abstract will be presented at a session entitled, "Gene Therapies", which will run from 12:30 PM until 2:30 PM on Monday, November 16th.

The conference, hosted by AACR, NCI and EORTC, will bring together academics and scientists and representatives from the pharmaceutical industry to discuss innovation in drug development, target selection and the impact of new discoveries in molecular and cell biology. The event has been organized to reflect the many recent advances in the early development of promising new compounds, which are in different levels of preclinical and clinical development.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Senesco Announces H1N1 Influenza Survival Test Results in Mice
2. Senesco Chooses VGXI to Produce Factor 5A Plasmid
3. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
4. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
5. Senesco Technologies Initiates Preclinical Studies for Cancer Target
6. Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting
7. Dr. Brad Vince, with Vince and Associates Clinical Research, Presents at the Exploratory Development World Congress 2009
8. Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration
9. Dr. Julian Henley MD Presents BioMatrix Lift
10. Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology
11. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Mich. , May 19 Stryker Corporation (NYSE: ... has informed the Company that the actions undertaken to address issues raised ... , , , ... Warning Letter from FDA regarding compliance with certain quality system requirements at ...
... SAN FRANCISCO, Calif. , May 19 ... studies was published in The Lancet on ... elevated levels of lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular-specific ... coronary heart disease similar in magnitude to that with ...
Cached Medicine Technology:Stryker Announces Resolution of Two FDA Warning Letters 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 3
(Date:4/17/2014)... NY In a review published in the April ... president of The Feinstein Institute for Medical Research, says ... medical community,s approach to treating sepsis, which ... Americans. , Sepsis occurs when molecules released into the ... throughout the body. Inflammation is necessary for maintaining good ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... Calif., April 17, 2014 By discovering a new ... after a stroke, researchers at UC Irvine and the ... that may limit or prevent stroke-induced brain damage. , ... fourth-leading cause of death and primary reason for disability ... in a stroke and lets blood-borne material into the ...
(Date:4/17/2014)... online has the potential to ward off depression among ... research published online in The Journals of ... . In the article " Internet Use and Depression ... Longitudinal Analysis ," the authors report that Internet use ... percent among their study sample. , Late-life depression ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... Yarl’s Wood one of the country's biggest immigration detention ... long-term detainees, according to the report of the prison ... launched an inquiry into healthcare at Yarl's Wood Immigration ... treatment of two female asylum seekers from Uganda. ...
... A ban on smoking cigarettes in public places such as ... recommendation// made by a panel consisting of members from the ... that about 3000 to 5000 people exposed to passive smoking ... However a statutory ban on smoking in France could trigger ...
... introduced a new medical device to facilitate the ... ,The Cuban-made equipment, Digital ANGIODIN PD-3000 ... dysfunction and micro and macro vessel failures at ... Tuesday. ,The equipment is simple in ...
... Nobel prize for medicine has been conferred on two Americans, ... of the Harvard University//, for their discovery of ‘RNA interference’, ... humans. , ‘RNA interference’ involves the silencing ... role in the regulation of gene expression, controls the activity ...
... announced on Tuesday the acquisition of Pinewood Laboratories// Limited ... broaden its presence in the European market. ,'This ... over Britain, Ireland and Germany,' Wockhardt chairman Habil Khorakiwala ... million, accounting for almost half of Wockhardt's total sales,' ...
... after the devastating earthquake of 8 October 2005 in ... at risk, facing a second winter without permanent shelter.// ... left around 3.5 million homeless. Estimates have shown that ... while recent landslides and flooding have left most quake ...
Cached Medicine News:Health News:Nobel Prize for Gene ‘Silencing 2Health News:Survivors of Pakistan Earthquake Still at Risk 2
Malaria device / strip (2 line, P.f.-HRP2 Test)...
... Trinity Biotech Uni-Gold™ Pf Malaria Test ... vitro, the presence of Plasmodium ... test is an antigen-capture assay detecting ... histidine- rich protein II (PfHRP- II), ...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
Medicine Products: